MX2016013439A - Formas solidas de un compuesto farmaceuticamente activo. - Google Patents

Formas solidas de un compuesto farmaceuticamente activo.

Info

Publication number
MX2016013439A
MX2016013439A MX2016013439A MX2016013439A MX2016013439A MX 2016013439 A MX2016013439 A MX 2016013439A MX 2016013439 A MX2016013439 A MX 2016013439A MX 2016013439 A MX2016013439 A MX 2016013439A MX 2016013439 A MX2016013439 A MX 2016013439A
Authority
MX
Mexico
Prior art keywords
solid forms
active compound
pharmaceutically active
compound
compositions
Prior art date
Application number
MX2016013439A
Other languages
English (en)
Inventor
Benz Rudolf
Diodone Ralph
Jia Zhongjiang
Patel Bharat
Schwitter Urs
Duk Soon Choi
Yan Ningxin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016013439A publication Critical patent/MX2016013439A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente solicitud describe formas sólidas del compuesto(1) los métodos para producirlos, así como composiciones que comprenden dichas formas sólidas.
MX2016013439A 2014-04-15 2015-04-13 Formas solidas de un compuesto farmaceuticamente activo. MX2016013439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461979649P 2014-04-15 2014-04-15
PCT/EP2015/057937 WO2015158648A1 (en) 2014-04-15 2015-04-13 Solid forms of a pharmaceutically active compound

Publications (1)

Publication Number Publication Date
MX2016013439A true MX2016013439A (es) 2016-11-17

Family

ID=52815005

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013439A MX2016013439A (es) 2014-04-15 2015-04-13 Formas solidas de un compuesto farmaceuticamente activo.

Country Status (18)

Country Link
US (1) US10227298B2 (es)
EP (2) EP3459933B1 (es)
JP (2) JP6621761B2 (es)
KR (1) KR20160138307A (es)
CN (1) CN106458886A (es)
AR (1) AR100095A1 (es)
AU (1) AU2015249018A1 (es)
BR (1) BR112016023767A2 (es)
CA (1) CA2943571A1 (es)
ES (1) ES2928706T3 (es)
IL (1) IL247974A0 (es)
MA (1) MA39877A (es)
MX (1) MX2016013439A (es)
PL (1) PL3459933T3 (es)
RU (1) RU2016144187A (es)
SG (1) SG11201608559QA (es)
WO (1) WO2015158648A1 (es)
ZA (1) ZA201606653B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
WO2019213106A1 (en) 2018-04-30 2019-11-07 Teva Pharmaceuticals International Gmbh Solid state forms of idasanutlin
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
EP2854800B1 (en) * 2012-05-30 2018-03-28 F.Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
UA116004C2 (uk) * 2013-01-22 2018-01-25 Ф. Хоффманн-Ля Рош Аг Фармацевтична композиція з покращеною біодоступністю
EP2958893B1 (en) 2013-02-21 2017-05-03 F. Hoffmann-La Roche AG Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide

Also Published As

Publication number Publication date
EP3459933A3 (en) 2019-05-29
EP3459933A2 (en) 2019-03-27
RU2016144187A (ru) 2018-05-16
ZA201606653B (en) 2018-05-30
AU2015249018A1 (en) 2016-10-06
BR112016023767A2 (pt) 2017-08-15
EP3131878A1 (en) 2017-02-22
RU2016144187A3 (es) 2018-11-13
AR100095A1 (es) 2016-09-07
EP3459933B1 (en) 2022-08-24
ES2928706T3 (es) 2022-11-22
US10227298B2 (en) 2019-03-12
CA2943571A1 (en) 2015-10-22
JP6621761B2 (ja) 2019-12-18
MA39877A (fr) 2017-02-22
WO2015158648A1 (en) 2015-10-22
IL247974A0 (en) 2016-11-30
CN106458886A (zh) 2017-02-22
US20170037005A1 (en) 2017-02-09
PL3459933T3 (pl) 2023-01-23
KR20160138307A (ko) 2016-12-02
SG11201608559QA (en) 2016-11-29
JP2019055960A (ja) 2019-04-11
JP6887980B2 (ja) 2021-06-16
JP2017511362A (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
SI3577110T1 (sl) 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
MX2022016566A (es) Composiciones que comprenden una caseina y metodos para producir las mismas.
MX2018006148A (es) Inhibidores de cxcr2.
UY36275A (es) Compuestos aminopirimidinilo
MX2019011496A (es) Composiciones de niraparib.
MX2015016783A (es) Inhibidores de moleculas pequeñas de fibrosis.
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
WO2015191945A3 (en) Solid state forms of sofosbuvir
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12018500903A1 (en) Pyranodipyridine compound
IL284800A (en) Methods, uses and compositions
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
WO2015104720A3 (en) Parenteral compositions of bendamustine
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
WO2015111004A3 (en) Improved process for the preparation of chlorophenyl trifluoroethanone
WO2016181204A8 (en) Method of making a mercury based compound, mercury based compound, methods of using the mercury based compound and uses of the mercury based compound
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
IN2014MU00859A (es)
MX2019000977A (es) Composiciones farmacéuticas a base de curcumina y procedimientos para su fabricación.